Zai Lab Ltd
HKEX:9688
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.62
25.65
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Zai Lab Ltd
Zai Lab Ltd
Accrued Liabilities
Zai Lab Ltd
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zai Lab Ltd
HKEX:9688
|
Accrued Liabilities
$70.6m
|
CAGR 3-Years
55%
|
CAGR 5-Years
80%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Accrued Liabilities
¥2.6B
|
CAGR 3-Years
49%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Accrued Liabilities
¥268.5m
|
CAGR 3-Years
37%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Accrued Liabilities
¥164.1m
|
CAGR 3-Years
50%
|
CAGR 5-Years
30%
|
CAGR 10-Years
19%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Accrued Liabilities
¥325.2m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
21%
|
CAGR 10-Years
45%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Accrued Liabilities
¥116.1m
|
CAGR 3-Years
52%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
Zai Lab Ltd
Glance View
Zai Lab Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-09-28. Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The firm is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The firm has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
See Also
What is Zai Lab Ltd's Accrued Liabilities?
Accrued Liabilities
70.6m
USD
Based on the financial report for Dec 31, 2023, Zai Lab Ltd's Accrued Liabilities amounts to 70.6m USD.
What is Zai Lab Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
80%
Over the last year, the Accrued Liabilities growth was 28%. The average annual Accrued Liabilities growth rates for Zai Lab Ltd have been 55% over the past three years , 80% over the past five years .
You don't have any saved screeners yet
